Recap: Exagen Q3 Earnings

Shares of Exagen XGN were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 83.65% year over year to ($0.34), which beat the estimate of ($0.48).

Revenue of $10,775,000 up by 3.22% from the same period last year, which beat the estimate of $8,880,000.

Outlook

Exagen hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 10, 2020

Time: 04:30 PM

ET Webcast URL: http://public.viavid.com/player/index.php?id=141944

Technicals

Company's 52-week high was at $29.86

52-week low: $10.29

Price action over last quarter: Up 25.84%

Company Profile

Exagen Diagnostics Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.